Correction to: Scientific Reports https://doi.org/10.1038/s41598-023-41528-0, published online 04 September 2023

The original version of this Article contained errors.

In the original version of this Article, the β-Catenin gene and the c-Myc gene were misspelt as ‘catenin gene’ and ‘Myc’.

As a result, in the Abstract section,

“After 48 h, Compound MDAU(4) had a stronger inhibitory effect on the growth of A549 and Caco2, compared to standard values. Then, using QRT-PCR, the appearance sites of the genes -Catenin, c-Myc, Cyclin D1, and MMP7 in A549 cells were examined. By reducing the expression levels of the Wnt signaling cascade genes -Catenin, c-Myc, Cyclin D1, and MMP7 when administered to A549 cells, compound MDAU(4) was shown in this investigation to be a viable candidate compared to lung cancer.”

now reads,

“After 48 h, Compound MDAU(4) had a stronger inhibitory effect on the growth of A549 and Caco2, compared to control cells. Then, using QRT-PCR, the appearance sites of the genes β-Catenin, c-Myc, Cyclin D1, and MMP7 in A549 cells were examined. By reducing the expression levels of the Wnt signalling cascade genes (β-Catenin, c-Myc, Cyclin D1, and MMP7) when administered to A549 cells, compound MDAU(4) was shown in this investigation to be a viable candidate compared to lung cancer.”

In the Introduction,

“Additionally, we examined these cellulosic derivatives with cytotoxic effects on lung cancer cells (A549) and colon cancer cells (Caco2), and we then examined the levels of -Catenin, Myc, Cyclin D1, and MMP7 gene expression in A549 cells.”

now reads,

“Additionally, we examined these cellulosic derivatives with cytotoxic effects on lung cancer cells (A549) and colon cancer cells (Caco2), and we then examined the levels of β-Catenin, c-Myc, Cyclin D1, and MMP7 gene expression in A549 cells.”

Under the Molecular studies section

“The A549 cells preserved with uracil pyrazole cellulose MDAC(2), MDAU(4), MDAP(5) on mRNA expression levels β-Catenin, Myc, Cyclin D1, and MMP7 genes were estimated utilizing IC50 standards of these heterocycles later 2 days and were estimated through calculating the percentage of its expression to that of β-Actin and in comparison to control values. From earlier analysis, it is fit recognized that the expression levels of β-Catenin, Myc, Cyclin D1, and MMP7 are up-regulated in A549 cells48,49. The Wnt signaling pathway is a complex pathway that regulates cell growth and proliferation50. The abnormal excitation of the pathway due to genetic mutation or increased stability can activate the abnormal expression of downstream target genes, including, Myc, Cyclin, and MMP-7, which can lead to cell proliferation, inhibition of cell apoptosis, and tumor formation51.”

now reads,

“The impact of A549 cells treated with uracil pyrazole cellulose MDAC(2), MDAU(4), MDAP(5) on mRNA expression levels β-Catenin, c-Myc, Cyclin D1, and MMP7 genes were estimated utilizing IC50 values of these heterocycles later 2 days and were estimated through calculating the percentage of its expression to that of β-Actin and in comparison to control values. From earlier studies, it is fit recognized that the expression levels of β-Catenin, c-Myc, Cyclin D1, and MMP7 are up-regulated in A549 cells48,49. The Wnt signaling pathway is a complex pathway that regulates cell growth and proliferation50. The abnormal excitation of the pathway due to genetic mutation or increased stability can activate the abnormal expression of downstream target genes, including, c-Myc, Cyclin, and MMP-7, which can lead to cell proliferation, inhibition of cell apoptosis, and tumor formation51.”

and where

“Besides, compound MDAU(4) exhibited a significant reduction in levels of β-Catenin, Myc, Cyclin D1, and MMP7 genes in A549 cells compared to control values (Fig. 8). From obtained results, we found that compound MDAU(4) is the most promising anticancer agent against A549 cancer cells through the reduction of expression levels of β-Catenin, Myc, Cyclin D1, and MMP7 genes compared to control values41,50.”

Figure 8
figure 8

Effect of Doxorubicin, MDAC(2), MDAU(4) and MDAP(5) on levels of β-Catenin, c-Myc, Cyclin D1 and MMP7 genes in A549 cells. Data are represented as mean ± SEM, Data were reproducible, *P < 0.05.

Full size image

now reads,

“Besides, compound MDAU(4) exhibited a significant reduction in levels of β-Catenin, c-Myc, Cyclin D1, and MMP7 genes in A549 cells compared to control values (Fig. 8). From obtained results, we found that compound MDAU(4) is the most promising anticancer agent against A549 cancer cells through the reduction of expression levels of β-Catenin, c-Myc, Cyclin D1, and MMP7 genes compared to control values41,50.”

Finally, in the Conclusion

“The Wnt genes (-Catenin, Myc, Cyclin D1, and MMP7) are likewise expressed at lower levels in A549 cells after 48 h.”

now reads,

“And also, it was a reduced expression levels of the Wnt genes (β-Catenin, c-Myc, Cyclin D1, and MMP7) in A549 cells after 48 h.”

In addition, in the original version of Fig. 8, the statistical analysis did not contain error bars of SEM and stars of significance, and the gene names were not mentioned on the X-axis. The incorrect Fig. 8 and its accompanying legend appear below.

The original version of this Article has been corrected.